Jason E Farrar, MD

Research Program: Cancer Biology Faculty Rank: Associate Professor Campus: Arkansas Children's Hospital College: College of Medicine Department: Pediatrics

Cancer Research Interest

• Disease Site Focus: Pediatric Oncology, Hematologic Malignancies
• Research Focus Area: Treatment, Informatics, Detection, Diagnosis/ Prognosis
• Type of Research: Clinical, Translational
• Research Interest Statement: I am a pediatric hematologist/oncologist with clinical interests in childhood leukemia, lymphomas and cancer-prone disorders such as inherited bone marrow failure and myelodysplastic syndromes. Our research program focuses on understanding the genetic basis of abnormal bone marrow function that underlies these diseases in children in order to identify new therapeutic options and improve treatment outcomes.

Contact Information

• Email Address: JEFARRAR@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• UAMS ACHRI Flow Through – GR039178
  “GR039178-Farrar-ACRI Proteogenomics Core”
  Principal Investigator
  07/01/22 – 06/30/23

Publications

• Bertrums EJM, Smith JL, Harmon L, [et al., including Farrar JE]. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023. PMID: 36815378.
• Farrar JE, Smith JL, Othus M, [et al.]. Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023:JCO2201114. PMID: 36795987.
• Huang BJ, Smith JL, Farrar JE, [et al.]. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nature communications. 2022 13(1):5487. PMID: 36123353. PMCID: PMC9485122.
• Hu Y, Caldwell KJ, Onciu M, [et al., including Farrar JE]. CPX-351 Induces Remission in Newly Diagnosed Pediatric Secondary Myeloid Malignancies. Blood advances. 2021. PMID: 34710216. PMCID: PMC8791570.
• Huang BJ, Smith J, Wang J, [et al., including Farrar JE]. CBFB-MYH11 Fusion Transcripts Distinguish Acute Myeloid Leukemias with Distinct Molecular Landscapes and Outcomes. Blood advances. 2021. PMID: 34547772. PMCID: PMC9153007.
• Gill PS, Yu FB, Porter-Gill PA, [et al., including Farrar JE]. Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital. Journal of personalized medicine. 2021 11(5). PMID: 34064668. PMCID: PMC8150685.
• Douglass DP, Stine KC, Farrar JE. A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance. Journal of pediatric hematology/oncology. 2021. PMID: 33633026.
• Li J, Galbo PM Jr, Gong W, [et al., including Farrar JE]. ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. Nature communications. 2021 12(1):1045. PMID: 33594072. PMCID: PMC7886901.
• Bolouri H, Ries R, Pardo L, [et al., including Farrar JE]. A B-cell developmental gene regulatory network is activated in infant AML. PloS one. 2021 16(11):e0259197. PMID: 34793513. PMCID: PMC8601427.
• Hecht A, Meyer JA, Behnert A, [et al., including Farrar JE]. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica. 2020 Online ahead of print. PMID: 33375775. PMCID: PMC8719097.
• Vlachos A, Atsidaftos E, Lababidi ML, [et al., including Farrar JE]. L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry. Pediatric blood & cancer. 2020:e28748. PMID: 33025707. PMCID: PMC8273758.
• Gianferante DM, Wlodarski MW, Atsidaftos E, [et al., including Farrar JE]. Genotype-phenotype association and variant characterization in Diamond-Blackfan anemia caused by pathogenic variants in RPL35A. Haematologica. 2020. PMID: 32241839. PMCID: PMC8094096.
• Smith JL, Ries RE, Hylkema T, [et al., including Farrar JE]. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 26(3):726-737. PMID: 31719049. PMCID: PMC7002196.
• Vlachos A, Tackett A, Osorio DS, [et al., including Farrar JE]. Increased Prevalence of Congenital Heart Disease in Children With Diamond Blackfan Anemia Suggests Unrecognized Diamond Blackfan Anemia as a Cause of Congenital Heart Disease in the General Population: A Report of the Diamond Blackfan Anemia Registry. Circulation. Genomic and precision medicine. 2018 11(5):e002044. PMID: 29748317. PMCID: PMC5951415.
• Bolouri H, Farrar JE, Triche T Jr, [et al.]. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature medicine. 2018 24(1):103-112. PMID: 29227476. PMCID: PMC5907936.
• Farrar JE, Neuberg D, Triche T Jr, Bodine DM. Response: Making "perfect" the enemy of good. Blood. 2017 130(9):1168-1169. PMID: 28754684. PMCID: PMC5580277.
• O'Brien KA, Farrar JE, Vlachos A, [et al.]. Molecular convergence in ex vivo models of Diamond-Blackfan anemia. Blood. 2017 129(23):3111-3120. PMID: 28377399. PMCID: PMC5465839.
• Gore L, Triche TJ Jr, Farrar JE, [et al.]. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clinical epigenetics. 2017 9:108. PMID: 29034009. PMCID: PMC5629751.
• Maxson JE, Ries RE, Wang YC, [et al., including Farrar JE]. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood. 2016 127(24):3094-8. PMID: 27143256. PMCID: PMC4911865.